SCHEMBL29655083

SCHEMBL29655083

COc1ccc(-c2ccc(N)c([N+](=O)[O-])c2)c(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.55
MAPT P10636 3/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
POLB P06746 1/20 0.55
CYP3A4 P08684 3/20 0.51
CYP1A1 P04798 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2E1 P05181 1/20 0.51
CYP2C8 P10632 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2A6 P11509 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP4B1 P13584 1/20 0.51
CYP2B6 P20813 1/20 0.51
CYP3A5 P20815 1/20 0.51
CYP2A7 P20853 1/20 0.51
CYP3A7 P24462 1/20 0.51
CYP2F1 P24903 1/20 0.51
CYP2C18 P33260 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29655119 0.85 MAPT (0.54) TDP1MAPTMEN1KMT2APOLB
SCHEMBL29655165 0.85 TDP1 (0.54) TDP1MAPTMEN1KMT2APOLB
SCHEMBL29655065 0.83 TDP1 (0.58) TDP1MAPTMEN1KMT2APOLB
SCHEMBL5952257 0.83 TDP1 (0.58) TDP1MAPTMEN1KMT2APOLB
SCHEMBL717794 0.83 MAPT (0.71) TDP1MAPTMEN1KMT2APOLB
SCHEMBL204041 0.82 ALDH1A1 (0.61) TDP1MAPTMEN1KMT2APOLB
SCHEMBL27774544 0.82 ALDH1A1 (0.61) TDP1MAPTMEN1KMT2APOLB
SCHEMBL10169410 0.81 APP (0.55) TDP1MAPTMEN1KMT2ACYP3A4
SCHEMBL9808940 0.81 MAPT (0.51) TDP1MAPTMEN1KMT2APOLB
Nitrogen SCHEMBL28840099 0.79 ALDH1A1 (0.58) TDP1MAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843874-B Phthalazine derivatives useful as inhibitors of PARP1, PARP2 and/or tubulin for the treatment of cancer 加利福尼亚大学董事会 2022-05-27 CN disclosed